Form D · Biotechnology
mirOculus Inc.
San Francisco, CA · CIK 0001639682
Offering snapshot reported Feb 25, 2021 · SEC filing
- Reported sold
- $20.2M Offering amount: $20.2M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 11, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2021 | Initial | $20,216,637 | No comparison | 15 | SEC filing |
| Feb 25, 2019 | Amendment | $25,382,097 | $8,170,733vs Aug 21, 2018 | 24 | SEC filing |
| Aug 21, 2018 | Initial | $17,211,364 | No comparison | 14 | SEC filing |
| Apr 21, 2015 | Initial | $2,824,400 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-390515
Source: Form D, filed Feb 25, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Foteini Christodoulou | Director |
| Ferran Galindo | Director |
| Mark Lewis | Director |
| Hector Sepulveda | Director |
| Alejandro Tocigl | Director, Executive |
| Pablo Patricio Zapata Aramburuzabala | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
458 Brannan St.
San Francisco, CA, 94107
San Francisco, CA, 94107